https://doi.org/10.4081/btvb.2023.92
Descriptive analysis of patients positive for anti-phospholipid antibodies included in two Italian registries
Submitted: 13 July 2023
Accepted: 20 September 2023
Published: 12 October 2023
Accepted: 20 September 2023
Abstract Views: 682
PDF: 187
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The definite diagnosis of antiphospholipid syndrome (APS) depends on the laboratory performance and clinicians’ interpretation. Results from two Italian inception cohort studies of anti-phospholipid antibodies (aPL)-positive subjects, the Italian Survey on ANtiphoSpholipid antibody Positive Individuals Registry (INSPIRE) and the Survey on AnTicoagulated Patients-RegisTry (START) have been compared. Data from INSPIRE were collected by rheumatologists of the FIRMA group while those of START by physicians working in Italian thrombosis centers. Evidence on several, still unraveled, clinical and methodological aspects of ‘real life’ aPL testing and APS diagnosis was collected. In this paper, we report the characteristics of 123 cases enrolled in INSPIRE and 229 in START registries, with particular reference to the reasons why these tests were requested, the obtained aPL profile, and consequent treatment. Laboratory testing for aPL in the absence of clinical criteria defining APS was more frequent in INSPIRE (p<0.0001). The rate of patients in classification category I (more than one aPL test positive) was significantly higher in START (p<0.0001) as well as the use of warfarin. A wide variety of treatments has been observed in patients in classification category II (single aPL positivity). These data indicate that there is a need to harmonize many aspects among the various specialists dealing with APS.
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
DOI: https://doi.org/10.1111/j.1538-7836.2006.01753.x
Cecchi I, Radin M, Rubini E, et al. Clinical manifestations in patients with antiphospholipid antibodies: Beyond thrombosis and pregnancy loss. Lupus 2021:961203321995248.
DOI: https://doi.org/10.1177/0961203321995248
Rosa RF, Ugolini-Lopes MR, Zeinad-Valim AK, et al. Difficult clinical situations in the antiphospholipid syndrome. Curr Rheumatol Rep 2015;17:29.
DOI: https://doi.org/10.1007/s11926-015-0502-7
Abreu MM, Danowski A, Wahl DG, et al. The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015;14:401-14.
DOI: https://doi.org/10.1016/j.autrev.2015.01.002
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019;78:1151-9.
DOI: https://doi.org/10.1136/annrheumdis-2020-218615
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
DOI: https://doi.org/10.1002/art.1780400928
Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
DOI: https://doi.org/10.1002/art.34473
Pengo V, Ruffatti A, Del Ross T, et al. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost 2013;11:1527-31.
DOI: https://doi.org/10.1111/jth.12264
Chayoua W, Kelchtermans H, Gris JC, et al. The (non-)sense of detecting anti-cardiolipin and anti-beta2glycoprotein I IgM antibodies in the antiphospholipid syndrome. J Thromb Haemost 2020;18:169-79.
DOI: https://doi.org/10.1111/jth.14633
Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019;78:1296-304.
DOI: https://doi.org/10.1136/annrheumdis-2019-215213
Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 2013;122:817-24.
DOI: https://doi.org/10.1182/blood-2013-04-496257
El Hasbani G, Viola M, Sciascia S, et al. Antiphospholipid Antibodies in Inflammatory and Autoimmune Rheumatic and Musculoskeletal Diseases Beyond Lupus: A Systematic Review of the Available Evidence. Rheumatol Ther. 2021;8:81-94.
DOI: https://doi.org/10.1007/s40744-020-00273-w
How to Cite
Pengo, V., Sarti, L., Antonucci, E., Di Agostino, S., Bison, E., Denas, G., … FIRMA group and START collaborators, on behalf of. (2023). Descriptive analysis of patients positive for anti-phospholipid antibodies included in two Italian registries. Bleeding, Thrombosis and Vascular Biology, 2(3). https://doi.org/10.4081/btvb.2023.92
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Most read articles by the same author(s)
- Daniela Poli, Emilia Antonucci, Gualtiero Palareti, Roberto Facchinetti, Pietro Falco, Giuseppina Serricchio, Teresa Lerede, Lucilla Masciocco, Paolo Gresele, Sophie Testa, Major bleedings in mechanical prosthetic heart valves patients on Vitamin K antagonist treatment. Data from the PLECTRUM Study , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
- Paolo Simioni, Vittorio Pengo, Paolo Prandoni, Thrombosis and hemostasis at the University of Padua: a reappraisal on the occasion of its 800th year of history , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Cristina Legnani, Michela Cini, Sophie Testa, Alberto Tosetto, Claudia Dellanoce, Stefania Bellesso, Giuseppe Carli, Ilaria Nichele, Laura Lissandrini, Serena Zorzi, Emilia Antonucci, Gualtiero Palareti, Evaluation of Coaguchek®Pro II coagulation testing device performance to assess direct oral anticoagulant action. The DOAC-CHECK study , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Daniela Poli, Walter Ageno, Emilia Antonucci, Salvatore Bradamante, Eugenio Bucherini, Paolo Chiarugi, Antonio Chistolini, Benilde Cosmi, Anna Falanga, Antonio Insana, Domenico Lione, Rosa Maria Lombardi, Giuseppe Malcangi, Rossella Marcucci, Giuliana Martini, Lucilla Masciocco, Carmelo Paparo, Daniele Pastori, Simona Pedrini, Vittorio Pengo, Pasquale Pignatelli, Andrea Toma, Sophie Testa, Gualtiero Palareti, Management of anticoagulation in atrial fibrillation patients in Italy: insight from the Atrial Fibrillation-Survey on Anticoagulated Patients Register (AF-START) , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Gualtiero Palareti, Paolo Prandoni, Cristina Legnani, Emilia Antonucci, Serena Zorzi, Alberto Tosetto, Lorenza Bertù, Sophie Testa, Vittorio Pengo, Walter Ageno, Ida Martinelli, Benilde Cosmi, Eugenio Bucherini, Daniela Poli, Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Gualtiero Palareti, The diagnostic procedure for subjects with suspected pulmonary embolism. A recent comparison among the recommendations available from the international guidelines , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 1 (2024)
- Gianfranco De Girolamo, Luca Sarti, Sonia Cecoli, Karin Bonora, Chiara Ajolfi, Francesco Bellelli, Valeria Coluccio, Gualtiero Palareti, Marco Marietta, Safety and efficacy of treatment with vitamin K antagonists in patients managed in a network of anticoagulation services or as routine general care , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Daniela Poli, Riccardo Tartaglia, Doris Barcellona , Paolo Bucciarelli , Antonio Ciampa, Elvira Grandone, Giuseppe Malcangi, Giuseppe Rescigno, Vincenzo Toschi, Sophie Testa, Alessandro Squizzato, Attitude to clinical research among health professionals affiliated with the Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
Similar Articles
- Juan Eirís, Marina Suárez-Terrón, Pablo Granados, David Martínez-Campuzano, Ana Rosa Cid, Saturnino Haya, Santiago Bonanad, Allopurinol-induced acquired von Willebrand syndrome , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 4 (2023)
- Silvia Cardi, Filippo Catalani, Luca Valerio, Stefano Barco, From rare to aware: confronting Lemierre syndrome , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 3 (2024)
- Paolo Prandoni, New perspectives for prevention of the post-thrombotic syndrome , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Luca Barcella, Chiara Ambaglio, Paolo Gritti, Francesca Schieppati, Varusca Brusegan, Eleonora Sanga, Marina Marchetti, Luca Lorini, Anna Falanga, Long-term persistence of high anti-PF4 antibodies titer in a challenging case of AZD1222 vaccine-induced thrombotic thrombocytopenia , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Ottavia Borghese, Claudio Vincenzoni, Commentary on “Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicenter, open-label, randomized controlled trial” , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Matteo Guarascio, Gerardo Nicola Pititto, Alessia Abenante, Marco Paolo Donadini, Distal deep vein thrombosis: is there a way out of this dark forest? , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Domenico Prisco, Irene Mattioli, Raffaele De Caterina, Alessandra Bettiol, The new era of anticoagulation: factor XI and XII inhibitors , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Giovanni Tiscia, Elvira Grandone, Talking about assisted reproductive techniques and thromboembolic risk: everything we always wanted to know , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
- Luca Puccetti, Vincenzo Sammartano, Federico Caroni, Margherita Malchiodi, Paola Calzoni, Eleonora Franceschini, Lucrezia Galasso, Monica Bocchia, Safety of COVID-19 mRNA vaccination in patients with history of acquired hemophilia A: a case series , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Lisa Pieri, Silvia Linari, Francesca Salvianti, Monica Attanasio, Giancarlo Castaman, Impaired platelet function in Hermansky-Pudlak syndrome associated with novel mutations in HPS3, HPS6 and HPS8 genes , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 3 (2024)
You may also start an advanced similarity search for this article.
